Trial Profile
An Open-label, Pilot Study of RO5185426 in Previously Treated Metastatic Melanoma Patients With Brain Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Adverse reactions
- Sponsors Roche
- 24 Sep 2012 Results will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep/Oct 2012.
- 15 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2012 Actual patients number chnaged from 2 to 24 as reported by ClinicalTrials.gov.